Abbvie suing Amgen over its efforts to launch a Humira biosimilar is the first instance of parties not agreeing on which patents to be litigated under the BPCIA. The case poses the question of whether the patent dance strikes the right balance between parties
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Value-added services give in-house counsel the satisfaction that they are getting more value for money, while law firms get the opportunity to win more work
Benjamin Kelly, the firm’s fifth IP partner hire in a little over one year, has experience in patent and trade secret disputes involving complex technologies
Half-year Talent Tracker data shows Pierson Ferdinand was among the most prolific hirers in the US, while in Europe, there has been a notable UPC swing
Tobias Hahn explains how the firm's multi-jurisdictional setup enabled it to secure an injunction on behalf of Fujifilm relating to defendant Kodak’s non-UPC activity
July 21 2025
Gift this article
As a premium subscriber, you can gift this article for free
https://www.demo.com/demo-article/
Link copied to clipboard
You have reached the limit for gifting for this month
There was an error processing the request. Please try again later.